Tags

Type your tag names separated by a space and hit enter

Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer.
Br J Cancer. 2014 Jun 10; 110(12):2914-22.BJ

Abstract

BACKGROUND

Recently, fibroblast growth factor receptor 1 (FGFR1) was discovered in squamous cell carcinomas (SCC) of the lung with FGFR1 amplification described as a promising predictive marker for anti-FGFR inhibitor treatment. Only few data are available regarding prevalence, prognostic significance and clinico-pathological characteristics of FGFR1-amplified and early-stage non-small cell lung carcinomas (NSCLC). We therefore investigated the FGFR1 gene status in a large number of well-characterised early-stage NSCLC.

METHODS

FGFR1 gene status was evaluated using a commercially available fluorescent in situ hybridisation (FISH) probe on a tissue microarray (TMA). This TMA harbours 329 resected, formalin-fixed and paraffin-embedded, nodal-negative NSCLC with a UICC stage I-II. The FISH results were correlated with clinico-pathological features and overall survival (OS).

RESULTS

The prevalence of an FGFR1 amplification was 12.5% (41/329) and was significantly (P<0.0001) higher in squamous cell carcinoma (SCC) (20.7%) than in adenocarcinoma (2.2%) and large cell carcinoma (13%). Multivariate analysis revealed significantly (P=0.0367) worse 5-year OS in patients with an FGFR1-amplified NSCLC.

CONCLUSIONS

FGFR1 amplification is common in early-stage SCC of the lung and is an independent and adverse prognostic marker. Its potential role as a predictive marker for targeted therapies or adjuvant treatment needs further investigation.

Authors+Show Affiliations

Department of Radiation Oncology, University Hospital/Inselspital Bern and University of Bern, 3010 Bern, Switzerland.Institute for Pathology, University Hospital Basel, 4003 Basel, Switzerland.Institute for Pathology, University Hospital Basel, 4003 Basel, Switzerland.Institute for Pathology, University Hospital Basel, 4003 Basel, Switzerland.Institute for Pathology, University Bern, 3010 Bern, Switzerland.Division of General Thoracic Surgery, University Hospital/Inselspital Bern, 3010 Bern, Switzerland.Division of Thoracic Surgery, University Hospital Basel, 4031 Basel, Switzerland.1] Institute for Pathology, University Bern, 3010 Bern, Switzerland [2] Promed Laboratoire Médical, 1723 Marley, Switzerland.Institute for Pathology, University Hospital Basel, 4003 Basel, Switzerland.1] Institute for Pathology, University Hospital Basel, 4003 Basel, Switzerland [2] Institute for Pathology, University Bern, 3010 Bern, Switzerland.1] Institute for Pathology, University Hospital Basel, 4003 Basel, Switzerland [2] Institute for Pathology, University Bern, 3010 Bern, Switzerland.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

24853178

Citation

Cihoric, N, et al. "Prognostic Role of FGFR1 Amplification in Early-stage Non-small Cell Lung Cancer." British Journal of Cancer, vol. 110, no. 12, 2014, pp. 2914-22.
Cihoric N, Savic S, Schneider S, et al. Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer. Br J Cancer. 2014;110(12):2914-22.
Cihoric, N., Savic, S., Schneider, S., Ackermann, I., Bichsel-Naef, M., Schmid, R. A., Lardinois, D., Gugger, M., Bubendorf, L., Zlobec, I., & Tapia, C. (2014). Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer. British Journal of Cancer, 110(12), 2914-22. https://doi.org/10.1038/bjc.2014.229
Cihoric N, et al. Prognostic Role of FGFR1 Amplification in Early-stage Non-small Cell Lung Cancer. Br J Cancer. 2014 Jun 10;110(12):2914-22. PubMed PMID: 24853178.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer. AU - Cihoric,N, AU - Savic,S, AU - Schneider,S, AU - Ackermann,I, AU - Bichsel-Naef,M, AU - Schmid,R A, AU - Lardinois,D, AU - Gugger,M, AU - Bubendorf,L, AU - Zlobec,I, AU - Tapia,C, Y1 - 2014/05/22/ PY - 2013/12/27/received PY - 2014/03/13/revised PY - 2014/04/08/accepted PY - 2014/5/24/entrez PY - 2014/5/24/pubmed PY - 2014/10/4/medline SP - 2914 EP - 22 JF - British journal of cancer JO - Br J Cancer VL - 110 IS - 12 N2 - BACKGROUND: Recently, fibroblast growth factor receptor 1 (FGFR1) was discovered in squamous cell carcinomas (SCC) of the lung with FGFR1 amplification described as a promising predictive marker for anti-FGFR inhibitor treatment. Only few data are available regarding prevalence, prognostic significance and clinico-pathological characteristics of FGFR1-amplified and early-stage non-small cell lung carcinomas (NSCLC). We therefore investigated the FGFR1 gene status in a large number of well-characterised early-stage NSCLC. METHODS: FGFR1 gene status was evaluated using a commercially available fluorescent in situ hybridisation (FISH) probe on a tissue microarray (TMA). This TMA harbours 329 resected, formalin-fixed and paraffin-embedded, nodal-negative NSCLC with a UICC stage I-II. The FISH results were correlated with clinico-pathological features and overall survival (OS). RESULTS: The prevalence of an FGFR1 amplification was 12.5% (41/329) and was significantly (P<0.0001) higher in squamous cell carcinoma (SCC) (20.7%) than in adenocarcinoma (2.2%) and large cell carcinoma (13%). Multivariate analysis revealed significantly (P=0.0367) worse 5-year OS in patients with an FGFR1-amplified NSCLC. CONCLUSIONS: FGFR1 amplification is common in early-stage SCC of the lung and is an independent and adverse prognostic marker. Its potential role as a predictive marker for targeted therapies or adjuvant treatment needs further investigation. SN - 1532-1827 UR - https://www.unboundmedicine.com/medline/citation/24853178/Prognostic_role_of_FGFR1_amplification_in_early_stage_non_small_cell_lung_cancer_ DB - PRIME DP - Unbound Medicine ER -